145369-94-4

Basic information

• Product Name: 6-BROMO-4-HYDROXYQUINOLINE
• Synonyms: 4-HYDROXY-6-BROMOQUINOLINE;4,7-DICHLORO-8-METHYLQUINOLINE;6-BROMOQUINOLIN-4-OL;6-BROMOQUINOLIN-4-ONE;6-BROMO-4-QUINOLINOL;6-BROMO-4-HYDROXYQUINOLINE;6-BROMO-4(1H)-QUINOLONE;BUTTPARK 23\09-03
• CAS NO: 145369-94-4
• Molecular Formula: C₉H₆BrNO
• Molecular Weight: 224.05
• EINECS: -0
• Mol File: 145369-94-4.mol
• Article Data: 36

Chemical Properties

• Melting Point: 283°C(lit.)
• Boiling Point: 321.713 °C at 760 mmHg
• Flash Point: 148.367 °C
• Appearance: /
• Density: 1.62 g/cm³
• Vapor Pressure: 0.00109mmHg at 25°C
• Refractive Index: 1.643
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 3.83±0.40(Predicted)
• CAS DataBase Reference: 6-BROMO-4-HYDROXYQUINOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BROMO-4-HYDROXYQUINOLINE(145369-94-4)
• EPA Substance Registry System: 6-BROMO-4-HYDROXYQUINOLINE(145369-94-4)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22-36/37/38
• Safety Statements: 26-36/37/39
• HazardClass: IRRITANT
• Hazardous Substances Data: 145369-94-4(Hazardous Substances Data)

Usage

Chemical Properties

Tan powder

InChI:InChI=1/C10H7Cl2N/c1-6-8(11)3-2-7-9(12)4-5-13-10(6)7/h2-5H,1H3

Upstream product

• 98948-95-9 6-bromo-4-hydroxyquinoline-3-carboxylic acid 
• 2033-24-1 cycl-isopropylidene malonate 
• 106-40-1 4-bromo-aniline 
• 141-82-2 malonic acid 
• 122-51-0 orthoformic acid triethyl ester 
• 101937-44-4 diethyl 2-((4-bromophenylamino)methylene)malonate 
• 1320361-74-7 ethyl 3-(4-bromoanilino)propenoate 
• 15568-85-1 5-methoxymethylene-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 187278-01-9 5-(((4-bromophenyl)amino)methylene)-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 76228-06-3 6-bromo-2,3-dihydro-4(1H)-quinolinone 
• 1551219-53-4 C₁₃H₁₂BrNO₄ 
• 10174-70-6 2-carboxy-4-hydroxy-6-bromoquinoline 
• 122794-99-4 6-bromo-4-hydroxyquinoline-3-carboxylic acid ethyl ester 
• 149-73-5 trimethyl orthoformate 

Downstream Products

• 332366-39-9 1-benzyloxycarbonyl-6-bromo-4-oxo-4H-quinoline 
• 474707-37-4 6-(3-methyl-1-trityl-1H-4-pyrazolyl)-4-quinolinol 
• 1320361-51-0 6-bromo-1-methyl-3-phenylquinolin-4(1H)-one 
• 1320361-52-1 6-bromo-1-methyl-3-(4-methylphenyl)quinolin-4(1H)-one 
• 1320361-56-5 6-bromo-3-[(E)-2-(4-methoxyphenyl)ethen-1-yl]-1-methylquinolin-4(1H)-one 
• 927801-23-8 6-bromo-4-iodoquinoline 
• 1086062-66-9 GS⁽²⁶⁴⁾K₂₁₅₈ 
• 1086062-75-0 6-bromo-4-chloroquinoline hydrochloride 
• 1360537-71-8 4-fluoro-N-(2-methoxy-5-(4-(pyridazin-4-yl)quinolin-6-yl)pyridin-3-yl)-2-nitrobenzenesulfonamide 
• 1360537-72-9 2-fluoro-N-(2-methoxy-5-(4-(pyridazin-4-yl)quinolin-6-yl)pyridin-3-yl)-4-nitrobenzenesulfonamide 
• 1360537-73-0 2,4-difluoro-N-(2-hydroxy-5-(4-(pyridazin-4-yl)quinolin-6-yl)pyridin-3-yl)benzenesulfonamide 
• 1360537-75-2 2-[⁽¹⁸⁾F]fluoro-4-fluoro-N-(2-methoxy-5-(4-(pyridazin-4-yl)quinolin-6-yl)pyridin-3-yl)benzenesulfonamide 
• 1360537-76-3 2-fluoro-4-[⁽¹⁸⁾F]fluoro-N-(2-methoxy-5-(4-(pyridazin-4-yl)quinolin-6-yl)pyridin-3-yl)benzenesulfonamide 
• 1086063-18-4 6-bromo-4-(pyridazin-4-yl)quinoline 

Relevant articles and documents

Cu(I)-Catalyzed Alkynylation of Quinolones

Herein we report the first alkynylation of quinolones with terminal alkynes under mild reaction conditions. The reaction is catalyzed by Cu(I) salts in the presence of a Lewis acid, which is essential for the reactivity of the system. The enantioselective version of this transformation has also been explored, and the methodology has been applied in the synthesis of the enantioenriched tetrahydroquinoline alkaloid cuspareine.

QUINOLINE-BASED COMPOUNDS AND METHODS OF INHIBITING CDK8/19

Disclosed herein are quinoline-based compounds and method for inhibiting CDK8 or CDK19 for the intervention in diseases, disorders, and conditions. The quinoline-based composition comprise substituents at quinoline ring positions 4 and 6, wherein the substituent at position 4 is selected from a substituted or unsubstituted arylalkylamine or a substituted or unsubstituted arylhetrocyclylamine. Pharmaceutical compositions comprising the substituted qunioline compositions, methods of inhibiting CDK8 or CDK19, and methods of treating CDK8/19-associated diseases, disorders, or conditions are also disclosed.

BICYCLE TOPOISOMERASE I INHIBITING COMPOUNDS, PROCESS FOR PREPARATION AND USE THEREOF

The invention described herein relates to the compounds of Formula I for treating diseases and disorders for which inhibition or modulation of the topoisomerase I enzyme produces a physiologically beneficial response, in particular for the treatment of breast cancer. Also provided is the process of preparing compounds of Formula I.